本页面由Tiger Trade Technology Pte. Ltd.提供服务

Bicara Therapeutics

23.90
-0.4900-2.01%
盘后23.900.00000.00%19:30 EDT
成交量:49.64万
成交额:1,202.92万
市值:15.82亿
市盈率:-7.69
高:25.56
开:24.73
低:23.77
收:24.39
52周最高:30.99
52周最低:10.30
股本:6,617.29万
流通股本:5,230.21万
量比:1.00
换手率:0.95%
股息:- -
股息率:- -
每股收益(TTM):-3.1097
每股收益(LYR):-2.5230
净资产收益率:-41.01%
总资产收益率:-26.14%
市净率:3.37
市盈率(LYR):-9.47

数据加载中...

公司资料

公司名字:
Bicara Therapeutics
交易所:
NASDAQ
成立时间:
2018
员工人数:
103
公司地址:
116 Huntington Avenue,Suite 703,Boston,Massachusetts,United States
邮编:
02116
电话:
传真:
- -
简介:
Bicara Therapeutics Inc.于2018年12月12日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司,专注于为实体瘤开发双功能疗法。其主要候选药物ficerafusp alfa同时靶向EGFR和TGF-β通路,目前正在针对头颈部鳞状细胞癌进行一项关键性试验。

董事

名称
职位
Claire Mazumdar
Chief Executive Officer and Director
Michael Powell
Chairperson of the Board
Ryan Cohlhepp
President, Chief Operating Officer and Director
Carolyn Ng
Director
Christopher Bowden
Director
Heath Lukatch
Director
Jake Simson
Director
Kate Haviland
Director
Kiran Mazumdar Shaw
Director
Nils Lonberg
Director
Scott Robertson
Director
Vijay Kuchroo, D.V.M
Director

股东

名称
职位
Claire Mazumdar
Chief Executive Officer and Director
Ryan Cohlhepp
President, Chief Operating Officer and Director
Ivan Hyep
Chief Financial Officer
David Raben
Chief Medical Officer
Lara Meisner
Chief Legal Officer